Integrating ctDNA in Bladder Cancer: Emerging Trials and Practical Applications

In part five of this roundtable series, Dr. Shilpa Gupta and the panel debate the use of circulating tumor DNA (ctDNA) in managing bladder cancer, particularly in the perioperative setting. The panelists highlight the ongoing MODERN trial, which uses ctDNA as a tool for risk-adapted treatment strategies post-cystectomy. They also discuss the potential of the innovative “pretzel device” that locally elutes gemcitabine, combined with cetrelimab, an anti-PD1 inhibitor, and has shown promising outcomes.